Dynamic Anthropometrics in Pancreatic Cancer: Associations Between Body Composition Changes During Neoadjuvant Therapy and Survival Outcomes After Resection
- PMID: 39120842
- DOI: 10.1245/s10434-024-15975-6
Dynamic Anthropometrics in Pancreatic Cancer: Associations Between Body Composition Changes During Neoadjuvant Therapy and Survival Outcomes After Resection
Abstract
Background: Assessment of individual tumor biology and response to systemic therapy in pancreatic ductal adenocarcinoma (PDAC) remains a clinical challenge. The significance of anthropometric (body composition) changes during chemotherapy as a surrogate for tumor biology in the setting of localized PDAC is unknown.
Methods: A retrospective, single-institution analysis of patients with PDAC who received neoadjuvant therapy (NAT) and pancreatectomy from 2017 to 2021 was performed. Radiologic anthropometric analysis used artificial intelligence-driven software to segment and compute total and sub-compartment muscle area, adipose tissue area, and attenuation values at the level of the L3 vertebra. Kaplan-Meier survival estimates, log-rank tests, and multivariable Cox regression models were used in survival analyses.
Results: The inclusion criteria were met by 138 patients. Although decreases in muscle and adipose tissue areas during NAT were predominant, a subset of patients experienced an increase in these compartments. Increases in muscle greater than 5% (hazard ratio [HR], 0.352; 95% confidence interval [CI] 0.135-0.918; p = 0.033) and increases in adipose tissue greater than 15% (HR, 0.375; 95% CI 0.144-0.978; p = 0.045), were significantly associated with improved survival, whereas loss of visceral fat greater than 15% was detrimental (HR 1.853; CI 1.099-3.124; p = 0.021). No significant associations with single time-point anthropometrics were observed. Gains in total muscle and adipose mass were associated with improved pathologic response to systemic therapy and less advanced pathologic tumor stage.
Conclusions: Dynamic anthropometric analysis during NAT for PDAC is a stronger prognostic indicator than measurements taken at a single point in time. Repeated anthropometric analysis during preoperative chemotherapy may serve as a biomarker for individual tumor biology and response to therapy.
Keywords: Anthropometrics; Pancreatic cancer; Pathologic response; Survival.
© 2024. Society of Surgical Oncology.
References
-
- Boone BA, Steve J, Zenati MS, et al. Serum CA 19–9 response to neoadjuvant therapy is associated with outcome in pancreatic adenocarcinoma. Ann Surg Oncol. 2014;21:4351–8. https://doi.org/10.1245/s10434-014-3842-z . - DOI - PubMed
-
- Argiles JM, Lopez-Soriano FJ, Stemmler B, Busquets S. Cancer-associated cachexia: understanding the tumour macroenvironment and microenvironment to improve management. Nat Rev Clin Oncol. 2023;20:250–64. https://doi.org/10.1038/s41571-023-00734-5 . - DOI - PubMed
-
- Peixoto da Silva S, Santos JMO, Costa ESMP, Gil da Costa RM, Medeiros R. Cancer cachexia and its pathophysiology: links with sarcopenia, anorexia, and asthenia. J Cachexia Sarcopenia Muscle. 2020;11:619–35. https://doi.org/10.1002/jcsm.12528 . - DOI - PubMed - PMC
-
- Kordes M, Larsson L, Engstrand L, Lohr JM. Pancreatic cancer cachexia: three dimensions of a complex syndrome. Br J Cancer. 2021;124:1623–36. https://doi.org/10.1038/s41416-021-01301-4 . - DOI - PubMed - PMC
-
- Fang P, Zhou J, Xiao X, et al. The prognostic value of sarcopenia in oesophageal cancer: a systematic review and meta-analysis. J Cachexia Sarcopenia Muscle. 2023;14:3–16. https://doi.org/10.1002/jcsm.13126 . - DOI - PubMed
MeSH terms
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous
